Tumor lysis Syndrome in a Patient with Metastatic Breast Cancer Treated with Alpelisib.

Autor: Handy C; Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Wesolowski R; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Gillespie M; Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Lause M; Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Sardesai S; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Williams N; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Grimm M; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Kassem M; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Ramaswamy B; Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Jazyk: angličtina
Zdroj: Breast cancer : basic and clinical research [Breast Cancer (Auckl)] 2021 Aug 29; Vol. 15, pp. 11782234211037421. Date of Electronic Publication: 2021 Aug 29 (Print Publication: 2021).
DOI: 10.1177/11782234211037421
Abstrakt: Purpose: Tumor lysis syndrome (TLS) is a rare but life-threatening phenomenon that occurs mainly in patients with aggressive hematologic or highly chemotherapy sensitive solid tumors such as high-grade neuroendocrine carcinoma or testicular cancer. Tumor lysis syndrome is exceedingly rare in hormone receptor-positive, HER2-negative breast cancer. Furthermore, TLS following treatment with alpelisib, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor used to treat PIK3CA -mutated (gene encoding p110α subunit of PI3K), hormone receptor positive advanced breast cancer, has never been described in patients with nonhematologic malignancies.
Methods: In the following case, we present a patient with hormone receptor-positive, HER2-negative, PIK3CA -mutated metastatic breast cancer who developed TLS 12 days after starting fulvestrant and alpelisib.
Results: Patient was promptly treated with improvement in her renal function to baseline without requiring renal replacement therapy. Alpelisib was resumed at a reduced dose with no further complications.
Conclusion: Through this case, we discuss the potential complications of TLS and the importance of prompt recognition and treatment.
Competing Interests: Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
(© The Author(s) 2021.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje